



IDSAs

Infectious Diseases Society of America

2013-2014 BOARD OF DIRECTORS

President

Barbara E. Murray, MD, FIDSA
THE UNIVERSITY OF TEXAS HEALTH
SCIENCE CENTER
HOUSTON, TX

President-Elect

Stephen B. Calderwood, MD, FIDSA
MASSACHUSETTS GENERAL HOSPITAL
BOSTON, MA

Vice President

Johan S. Bakken, MD, PhD, FIDSA
ST. LUKE'S ID ASSOCIATES
DULUTH, MN

Secretary

Penelope H. Dennehy, MD, FIDSA
HASBRO CHILDREN'S HOSPITAL
PROVIDENCE, RI

Treasurer

Cynthia L. Sears, MD, FIDSA
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
BALTIMORE, MD

Immediate Past President

David A. Relman, MD, FIDSA
STANFORD UNIVERSITY SCHOOL OF MEDICINE
PALO ALTO, CA

Judith A. Aberg, MD, FIDSA

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
NEW YORK, NY

**Barbara D. Alexander, MD, MHS,
FIDSA**

DUKE UNIVERSITY MEDICAL CENTER
DURHAM, NC

Upton D. Allen, MD, FIDSA

HOSPITAL FOR SICK CHILDREN
TORONTO, ONTARIO, CANADA

Helen W. Boucher, MD, FIDSA

TUFTS MEDICAL CENTER
BOSTON, MA

R. Michael Buckley, MD, FIDSA

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
PHILADELPHIA, PA

Deborah Cotton, MD, MPH, FIDSA

BOSTON UNIVERSITY SCHOOL OF MEDICINE
BOSTON, MA

Stanley C. Deresinski, MD, FIDSA

STANFORD UNIVERSITY SCHOOL OF MEDICINE
PALO ALTO, CA

Louis B. Rice, MD

WARREN ALPERT MEDICAL SCHOOL
OF BROWN UNIVERSITY
PROVIDENCE, RI

Steven K. Schmitt, MD, FIDSA

CLEVELAND CLINIC
CLEVELAND, OH

Chief Executive Officer

Mark A. Leasure

IDSAs Headquarters

1300 Wilson Boulevard
Suite 300
Arlington, VA 22209
TEL: (703) 299-0200
FAX: (703) 299-0204
EMAIL ADDRESS:
info@idsociety.org
WEBSITE:
www.idsociety.org

August 28, 2014

Francis Collins, MD, PhD
Director
National Institutes of Health
1 Center Drive
Bethesda, MD 20892

Margaret Hamburg, MD
Commissioner
U.S. Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Dear Drs. Collins and Hamburg,


On behalf of the Infectious Diseases Society of America (IDSAs), I thank you for hosting the recent public workshop: The Development of New Antibacterial Products: Charting a Course for the Future. As you know, IDSAs has long been concerned with antibiotic resistance and the nearly dry antibiotic pipeline, and we were extremely pleased to participate in this important meeting to help advance antibiotic research and development (R&D). This workshop and the announcement of upcoming activities represented a significant advancement in the federal dialogue on addressing antibiotic resistance and the waning antibiotic pipeline. IDSAs is heartened to see strong commitment to these issues at such high levels of our government and broad participation among multiple key stakeholders.

In particular, IDSAs enthusiastically welcomes the announcement from the National Institutes for Health at the conclusion of the meeting of an upcoming public-private partnership (PPP) to address antibiotic development as well as an effort to establish a master clinical trials protocol. We offer you IDSAs's support, expertise and assistance in designing and implementing these activities through the active engagement of our existing volunteer committees, helping to identify individuals with specific expertise, and making available any capacity or resource that would be helpful to you.

IDSAs has long advocated for a high-level PPP with representation from the federal government, academia, industry, physicians and other key stakeholders, to promote innovation and improvement in the discovery, development, and evaluation of new antibiotics and diagnostics. Given the urgent need for these products and the significant scientific, economic, and regulatory challenges they face, these areas are well suited for a PPP to tackle. A new PPP in this space can complement other efforts to reinvigorate antibiotic development, such as the limited population antibiotic development (LPAD) approval mechanism and tax credits for antibiotic and diagnostic R&D, and offer welcome new approaches to early stage development and clinical trial design that would not be possible simply through individual stakeholders acting alone. We hope these efforts will also include a focus on diagnostic development, given the broad agreement that diagnostics are extremely valuable for identifying patients for antibiotic clinical trials and crucial for antibiotic stewardship.

Once again, thank you for your commitment to finding solutions to this critical public health threat. We look forward to hearing more details about the PPP, master clinical trials protocol and other plans in this area for the future. IDSA stands ready to help you in any way we can. If you have any questions or would like to share any information with IDSA, please do not hesitate to contact Amanda Jezek, IDSA's Vice President for Public Policy and Government Relations at ajezek@idsociety.org or 703-740-4790.

Sincerely,

A handwritten signature in black ink that reads "Barbara E. Murray M.D." The signature is written in a cursive style with a large, looped initial 'B'.

Barbara E. Murray, MD, FIDSA
President, IDSA